Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

473
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
473
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

2.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

737
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
737
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

1.3K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
1.3K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

2.0K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.0K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

607
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
607

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration from China: 48-week results from the PULSAR trial.

International journal of retina and vitreous·2026
Same author

A Water-Stable Ultramicroporous Metal-Organic Framework with Aromatic Pore Walls for Coal-Mine Methane Capture.

Inorganic chemistry·2026
Same author

Effectiveness of a comprehensive nursing prevention and control system for respiratory infections in fever clinics in the era of co-existence of multiple pathogens.

Frontiers in public health·2026
Same author

5'-NucA-SMCC-DM1 and 5'-NucA-SPDMV-DM1 are Potent Aptamer-Drug Conjugates against Pancreatic Cancer.

ACS omega·2026
Same author

A Case of Bulky Florid Bladder von Brunn's Nest.

Urology·2026
Same author

Correction: OXTR rs2254298 polymorphism influences escitalopram response in Generalized Anxiety Disorder: a sex-specific role for oxytocin signaling.

Frontiers in psychiatry·2025
Same journal

Meta-analysis of adverse events in clinical studies with antisense oligonucleotide therapies.

Molecular therapy. Nucleic acids·2026
Same journal

A versatile VLP-mediated CRISPR-RNP platform for precise genome editing and durable epigenome silencing in cancer.

Molecular therapy. Nucleic acids·2026
Same journal

Pyroptosis as a novel therapeutic target in glioblastoma multiforme: Mechanisms, molecular insights, and therapeutic potential.

Molecular therapy. Nucleic acids·2026
Same journal

Selection and validation of novel DNA aptamer panel co-specific to <i>Plasmodium falciparum</i> and <i>Plasmodium ovale</i> lactate dehydrogenase.

Molecular therapy. Nucleic acids·2026
Same journal

Therapeutic rescue of pathogenic asparaginyl-tRNA synthetase alleles.

Molecular therapy. Nucleic acids·2026
Same journal

Milk-derived extracellular vesicles loaded with miR-146a-5p as a novel therapeutic strategy for allergic airway inflammation.

Molecular therapy. Nucleic acids·2026
查看所有相关文章

相关实验视频

Updated: May 10, 2025

Harvesting Venom Toxins from Assassin Bugs and Other Heteropteran Insects
09:45

Harvesting Venom Toxins from Assassin Bugs and Other Heteropteran Insects

Published on: April 21, 2018

13.0K

结合性STING激动剂的激动剂.

Shuhao Qu1, Hong Dai2

  • 1School of Veterinary Medicine, Henan University of Animal Husbandry and Economy, Zhengzhou 450046, China.

Molecular therapy. Nucleic acids
|April 28, 2025
PubMed
概括
此摘要是机器生成的。

干扰素基因刺激剂 (STING) 激动剂对先天免疫非常重要. 本综述探讨了用于增强癌症免疫治疗的新型非循环二核酸 (CDN) STING激动剂和结合递送策略,解决了CDN的局限性.

关键词:
这些CDN是CDN.MT:交付策略的交付策略刺痛是一种刺痛.刺痛的激动剂是刺痛的激动剂临床试验是指临床试验中的临床试验.结合式的结合式的结合干扰素基因的刺激剂.

更多相关视频

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.6K
A "Dual-Addition" Calcium Fluorescence Assay for the High-Throughput Screening of Recombinant G Protein-Coupled Receptors
08:46

A "Dual-Addition" Calcium Fluorescence Assay for the High-Throughput Screening of Recombinant G Protein-Coupled Receptors

Published on: December 2, 2022

2.1K

相关实验视频

Last Updated: May 10, 2025

Harvesting Venom Toxins from Assassin Bugs and Other Heteropteran Insects
09:45

Harvesting Venom Toxins from Assassin Bugs and Other Heteropteran Insects

Published on: April 21, 2018

13.0K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.6K
A "Dual-Addition" Calcium Fluorescence Assay for the High-Throughput Screening of Recombinant G Protein-Coupled Receptors
08:46

A "Dual-Addition" Calcium Fluorescence Assay for the High-Throughput Screening of Recombinant G Protein-Coupled Receptors

Published on: December 2, 2022

2.1K

科学领域:

  • 免疫学 免疫学 免疫学
  • 分子生物学分子生物学
  • 在瘤学瘤学.

背景情况:

  • 天生的免疫系统提供了对病原体的第一道防线.
  • 干扰素基因刺激器 (STING) 是先天免疫的关键调节者,对于启动免疫反应至关重要.
  • STING激活触发下游信号通路,导致产生I型干扰素和炎症性细胞因子,增强适应性免疫和T细胞激活.

研究的目的:

  • 审查开发新的干扰素基因刺激剂 (STING) 激动剂,重点关注非循环二核酸 (CDN) 替代品.
  • 检查结合策略的有效性,以提供STING激动剂,特别是在癌症免疫治疗的背景下.
  • 讨论STING激动剂在癌症治疗临床应用中的当前挑战和未来潜力.

主要方法:

  • 关于最近在STING激动剂开发和输送系统方面的进展的文献综述.
  • 化学修饰和非CDN STING 激动剂设计的分析.
  • 对结合策略的评估,包括脂质体和纳米颗粒,用于STING激动剂的输送.
  • 专注于目前正在进行癌症免疫治疗临床试验的STING激动剂.

主要成果:

  • 循环二核酸 (CDN),天然的STING激动剂,面临的挑战包括不稳定性,高极性,系统毒性和有限的临床疗效.
  • 已有大量的努力被用于开发化学修饰的CDN和新型非CDNSTING激动剂.
  • 结合策略和基于纳米系统的交付显示出克服传统CDN局限性的承诺.
  • 几种STING激动剂正在临床试验中取得进展,这表明它们具有治疗潜力.

结论:

  • 新型STING激动剂和先进的输送系统对于克服CDN在癌症免疫治疗中的局限性至关重要.
  • 结合策略提供了一个有希望的方法来提高STING激动剂的稳定性,向性和有效性.
  • 需要进一步的研究和临床评估,才能充分发挥STING激动剂在治疗癌症方面的潜力.